Hydrochlorothiazide – Risk of non-menoloma skin cancer

Hydrochlorothiazide – Risk of non-menoloma skin cancer

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a new risk of non-melanoma skin cancer (NMSC) (basal cell carcinoma, squamous cell carcinoma) in patients treated with hydrochlorothiazide.

2019 Apr

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance